Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : BMS Announced End of OTC Products in China

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/08/2016 | 12:04pm CET

BEIJING, December 8, SinoCast -- US pharmaceutical giant Bristol-Myers Squibb on December 6 announced the end of initiative promotion of OTC products in China.

The company needs to lay off about 150 people, will send salaries to the laid-off staff to the end of February 2017 and announced its "N +1 +2 * average monthly income" compensation program.

The company peeled off its HIV drug research and development line this February, gave up the diabetes market this March, abolished the tumor division's Taxol product group and abandoned the entire cardiovascular business at the end of this August.

After the move, the company will just have virus and tumor business units in China.

© Sinocast, source Sinocast Beats

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
12:04p BRISTOL MYERS SQUIBB : BMS Announced End of OTC Products in China
12/06 BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimu..
12/05 BRISTOL MYERS SQUIBB : Encouraging Survival Observed With Opdivo (nivolumab) Plu..
12/01 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Yield New Information a..
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "IMMVIVUR" Filed
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "NIVDIREC" Filed
12/01 BRISTOL MYERS SQUIBB : Studies Conducted at Bristol-Myers Squibb on Alcohols Rec..
12/01 BRISTOL MYERS SQUIBB : European Commission Approves Bristol-Myers Squibb's Opdiv..
12/01 BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb Update Understandi..
12/01 BRISTOL MYERS SQUIBB : New Hepatitis C Virus Study Findings Reported from Bristo..
More news
Sector news : Pharmaceuticals - NEC
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
12/07DJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/07 ET TU, DONALD? DRUGS DIVE : What's Going On, And What's Next
12/07 Bristol-Myers Squibb's (BMY) Management Presents at Citi 2016 Global Healthca..
12/06 Nektar Therapeutics Is Attractive Ahead Of Multiple Catalysts
12/06 What Could Pfizer Do With Cash From A Tax Holiday
12/04 December 2016's 10 Worst CCC Stocks At Various Market Caps
Advertisement
Financials ($)
Sales 2016 19 331 M
EBIT 2016 5 346 M
Net income 2016 4 615 M
Debt 2016 160 M
Yield 2016 2,83%
P/E ratio 2016 20,12
P/E ratio 2017 19,49
EV / Sales 2016 4,78x
EV / Sales 2017 4,58x
Capitalization 92 319 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 62,1 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-19.70%92 319
JOHNSON & JOHNSON8.16%302 251
ROCHE HOLDING LTD.-19.14%190 015
PFIZER INC.-2.23%189 272
NOVARTIS AG-20.05%178 826
MERCK & CO., INC.13.71%165 594
More Results